AcelRx Pharmaceuticals (NASDAQ: ACRX)
AcelRx Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
AcelRx Pharmaceuticals Company Info
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.
News & Analysis
2 Penny Stocks That Could Make You Filthy Rich
AcelRx Pharmaceuticals and Sundial Growers could both be poised for a major growth spurt.
Why AcelRx Pharmaceuticals Stock Is Sinking Today
The company announced the pricing of a public stock offering.
Here's Why AcelRx Pharmaceuticals Fell as Much as 14% Today
The pharma announced first-quarter 2019 operating results.
3 Stocks Peter Lynch Would Love
They could be big winners for patient investors.
Why AcelRx Pharmaceuticals Stock Is Sinking Today
Investors wanted more good news than they got in the specialty-drug maker's fourth-quarter update.
3 Top Small-Cap Stocks to Buy Right Now
These three small-cap stocks have outstanding growth potential.
2 Biotech Penny Stocks to Buy Right Now
AcelRx and Novavax are two penny biotech stocks worth checking out in this latest market downturn.
3 Stocks to Hold for the Next 20 Years
When you invest in a business, you should expect to stay with it for the long haul.
Valuation
Earnings Transcripts
AcelRx Pharmaceuticals Inc (ACRX) Q1 2020 Earnings Call Transcript
ACRX earnings call for the period ending March 31, 2020.
AcelRx Pharmaceuticals Inc (ACRX) Q4 2019 Earnings Call Transcript
ACRX earnings call for the period ending December 31, 2019.
AcelRx Pharmaceuticals Inc (ACRX) Q3 2019 Earnings Call Transcript
ACRX earnings call for the period ending September 30, 2019.
AcelRx Pharmaceuticals Inc (ACRX) Q2 2019 Earnings Call Transcript
ACRX earnings call for the period ending June 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.